Javascript must be enabled to continue!
Comparing Tolerability and Toxicity of Calaspargase pegol and Pegaspargase in Pediatric Leukemia Patients
View through CrossRef
ABSTRACT:
Background:
Pegaspargase (PEG-ASP) and
calaspargase pegol (CAL-PEG) are long acting asparaginase formulations
used to treat acute leukemia. As of December 2022, CAL-PEG became the
standard formulation for pediatric patients less than 22 years of age.
The objective of this study was to compare real-world safety and
efficacy of the two formulations in pediatric patients at a single
institution.
Procedure:
A three-year retrospective
evaluation of PEG-ASP and CAL-PEG utilization was completed. Patients
treated at stand-alone children’s hospital for acute leukemia who
received at least one dose of long acting asparaginase therapy were
included. Incidence and severity of hypersensitivity reactions, silent
inactivation, thromboembolism, bleeding, pancreatitis, hepatotoxicity,
and hypertriglyceridemia were collected.
Results:
A
total of 103 patients were included, of whom 50 received CAL-PEG and 58
received PEG-ASP. In the CAL-PEG group, 10 patients
experienced a symptomatic hypersensitivity reaction, compared to
six patients in the PEG-ASP group (20.0% vs. 10.3%; p = 0.16). Eight
patients receiving CAL-PEG had a silent inactivation while compared to
three patients receiving PEG-ASP (16.0% vs. 5.2%; p = 0.18). There was
a higher rate of hyperbilirubinemia noted with PEG-ASP compared to
CAL-PEG (58.6% vs. 34.0%; p = 0.01). Other adverse effects, including
hypertriglyceridemia, thrombosis, bleeding, transaminitis, and
pancreatitis were comparable between the two groups.
Conclusions:
There were no significant differences found
between CAL-PEG and PEG-ASP in terms of hypersensitivity reactions and
silent inactivation. Most other adverse effects associated with
asparaginase therapy were also similar between the two groups.
Monitoring and preventative measures should continue for patients to
help prevent the adverse effects associated with CAL-PEG.
Title: Comparing Tolerability and Toxicity of Calaspargase pegol and Pegaspargase in Pediatric Leukemia Patients
Description:
ABSTRACT:
Background:
Pegaspargase (PEG-ASP) and
calaspargase pegol (CAL-PEG) are long acting asparaginase formulations
used to treat acute leukemia.
As of December 2022, CAL-PEG became the
standard formulation for pediatric patients less than 22 years of age.
The objective of this study was to compare real-world safety and
efficacy of the two formulations in pediatric patients at a single
institution.
Procedure:
A three-year retrospective
evaluation of PEG-ASP and CAL-PEG utilization was completed.
Patients
treated at stand-alone children’s hospital for acute leukemia who
received at least one dose of long acting asparaginase therapy were
included.
Incidence and severity of hypersensitivity reactions, silent
inactivation, thromboembolism, bleeding, pancreatitis, hepatotoxicity,
and hypertriglyceridemia were collected.
Results:
A
total of 103 patients were included, of whom 50 received CAL-PEG and 58
received PEG-ASP.
In the CAL-PEG group, 10 patients
experienced a symptomatic hypersensitivity reaction, compared to
six patients in the PEG-ASP group (20.
0% vs.
10.
3%; p = 0.
16).
Eight
patients receiving CAL-PEG had a silent inactivation while compared to
three patients receiving PEG-ASP (16.
0% vs.
5.
2%; p = 0.
18).
There was
a higher rate of hyperbilirubinemia noted with PEG-ASP compared to
CAL-PEG (58.
6% vs.
34.
0%; p = 0.
01).
Other adverse effects, including
hypertriglyceridemia, thrombosis, bleeding, transaminitis, and
pancreatitis were comparable between the two groups.
Conclusions:
There were no significant differences found
between CAL-PEG and PEG-ASP in terms of hypersensitivity reactions and
silent inactivation.
Most other adverse effects associated with
asparaginase therapy were also similar between the two groups.
Monitoring and preventative measures should continue for patients to
help prevent the adverse effects associated with CAL-PEG.
Related Results
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients with Severe Hemophilia A: Interim Results of a Post-Marketing, Interventional Study
Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients with Severe Hemophilia A: Interim Results of a Post-Marketing, Interventional Study
Abstract
Background
Damoctocog alfa pegol (BAY 94-9027, Jivi®) is an approved factor (F)VIII treatment indicated for use in previously treated patient...
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Abstract
Background: Leukemia affects approximately 45,000 people each year in the USA with more than 20,000 fatalities. Many leukemia patients experience initial re...
Pediatric Pilonidal Sinus Disease: A Single-Center Cohort Study of Clinical and Surgical Outcomes
Pediatric Pilonidal Sinus Disease: A Single-Center Cohort Study of Clinical and Surgical Outcomes
Abstract
Introduction: Pilonidal sinus disease is increasingly recognized in the pediatric population, yet evidence on its clinical characteristics and surgical outcomes in childre...
STAT3 Mutations in Large Granular Lymphocytic Leukemia
STAT3 Mutations in Large Granular Lymphocytic Leukemia
Abstract
Abstract 1606
Introduction:
Large granular lymphocytic leukemia (LGL leukemia) is a rare lymphoprolifera...
The Pediatric Anesthesiology Workforce: Projecting Supply and Trends 2015–2035
The Pediatric Anesthesiology Workforce: Projecting Supply and Trends 2015–2035
BACKGROUND:
A workforce analysis was conducted to predict whether the projected future supply of pediatric anesthesiologists is balanced with the requirements o...
ROR1 Expression Accelerates Leukemia Development in RORxTCL1 Transgenic Mice,
ROR1 Expression Accelerates Leukemia Development in RORxTCL1 Transgenic Mice,
Abstract
Abstract 3905
ROR1 is a receptor tyrosine kinase-like orphan receptor and an oncofetal protein that is expressed on chronic lymphocytic leuke...
The Geographic Distribution of Pediatric Anesthesiologists Relative to the US Pediatric Population
The Geographic Distribution of Pediatric Anesthesiologists Relative to the US Pediatric Population
BACKGROUND:
The geographic relationship between pediatric anesthesiologists and the pediatric population has potentially important clinical and policy implicati...

